In an interim analysis of a phase 1 trial of concurrent intrathecal and intravenous anti-PD1 delivery in patients with leptomeningeal disease and melanoma, treatment was feasible and well-tolerated with no dose-limiting toxicities.
- Isabella C. Glitza Oliva
- Sherise D. Ferguson
- Michael A. Davies